Parkinson's Disease Clinical Trial
Official title:
Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism
Parkinson's disease (PD) and Drug-induced Parkinsonism (DIP) can be clinically
indistinguishable and DIP sometimes represents "unmasking of underlying PD. The objective of
this study is to determine the relationship of underlying Parkinson's disease (PD) to the
incidence and clinical outcome in DIP using non-motor assessments as a marker for
nigrostriatal degeneration.
Research Design: This is a nested case-control design to investigate risk factors associated
with the development of DIP and persistent Parkinsonism after antipsychotic (AP) withdrawal
(a potential clinical marker of underlying PD). Target enrollment is 45 subjects.
Methodology: We will examine objective olfactory function (via objective olfactory testing),
other non-motor symptoms of PD (via standardized validated questionnaires), and motor
findings (via clinical exam and quantitative gait analysis) in: 1) DIP patients (30 subjects)
compared to AP-treated patients without Parkinsonism (15 subjects) and 2) patients with
persistent Parkinsonism compared to those whose symptoms resolve in the DIP cohort followed
prospectively after a change in AP treatment. Additionally, in patients where it was
performed clinically, we will evaluate dopamine transporter SPECT imaging (DaTI) as a marker
of nigrostriatal integrity examining the ability of qualitative and semi-quantitative
analysis to distinguish between pharmacologic and degenerative Parkinsonism. We will also
measure serum uric acid and Apolipoprotein A1, two putative biomarkers in early PD, and
examine their relationship with clinical and radiologic status.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
| Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
| Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
| Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
| Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
| Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
| Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
| Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
| Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
| Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
| Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
| Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
| Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
| Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
| Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
| Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 |